Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial

著者: Sonya Abraham, Helene Bæk Juel, Peter Fibiger Bang, Hannah M. Cheeseman, Rebecca Bach Dohn, Tom Cole, Max P Kristiansen, Karen Smith Korsholm, David Lewis, Anja Weinreich Olsen, Leon R. McFarlane, Suzanne Day, Sara Knudsen, Kjersti Moen, Morten Rühwald, Ingrid Kromann, Peter Andersen, Robin J. Shattock, Frank Follmann - The Lancet 2019 被引用: 205